We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Advanced Mass Spectrometry Could Provide Microscopic Clues to Beating Deadly Brain Tumors

By LabMedica International staff writers
Posted on 01 Nov 2022
Print article
Image: Claire Carter, Ph.D., an expert in MALDI, led the new research (Photo courtesy of CDI)
Image: Claire Carter, Ph.D., an expert in MALDI, led the new research (Photo courtesy of CDI)

Glioblastoma is one of the most difficult cancers, let alone diseases, to treat. The brain tumor presents a median survival rate of just 12 to 15 months. The cancer is especially hard to beat, since it presents so heterogeneously – with different tumor cell subtypes within the same tumor, which can all respond differently to therapy. The cancer also has a tendency to create aberrant small blood vessel networks quickly, helping it spread quickly – and making it particularly hard to defeat through traditional treatment pathways. Now, scientists have discovered that a critical new pathway to treating glioblastoma might be found in the complex diversity within the tumor tissue.

A team of scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI, Nutley, NJ, USA) deeply analyzed tumor tissue using an advanced mass spectrometry with special focus on lipids, a class of molecules that includes fats. The scientists assessed five human samples of brain tumor tissue. The team looked at a series of different lipids, in different sections of the tumor and the surrounding environment, and found a series of possible treatment candidates.

“Lipid ions presented here lay the foundation for future studies that are required to understand their interconnecting signaling pathways in relation to cell function, tumor progression, and resistance to therapy,” according to the paper. “Understanding their functional relevance is essential for the identification of new therapeutics based on lipid pathway targets.”

“In conclusion, high resolution MALDI MSI identified a number of lipids that differentiate tumor and endothelial cell subpopulations within human glioblastoma samples,” the authors write. “The heterogenous distributions… within these cell population further highlight the complexity of the glioblastoma TME.”

The scientists hypothesize that a multi-pronged approach may fare best against the stubborn cancer.

“Targeting several of these lipids and their signaling pathways simultaneously, however, may improve clinical outcome,” they write.

Related Links:
CDI

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.